Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
NICE issues new guidance for asthmaPharmacoEconomics & outcomes news, 2017-12, Vol.793 (1), p.35-35Cham: Springer International PublishingTexto completo disponível |
|
2 |
Material Type: Artigo
|
ADHD imposes substantial economic burden on societyPharmacoEconomics & outcomes news, 2021, Vol.872 (1), p.2-2Cham: Springer International PublishingTexto completo disponível |
|
3 |
Material Type: Artigo
|
Latest NICE draft guidance does not recommend elusulfase alfa for rare disorderPharmacoEconomics & outcomes news, 2021, Vol.892 (1), p.32-32Cham: Springer International PublishingTexto completo disponível |
|
4 |
Material Type: Artigo
|
NICE draft guideline on pelvic floor dysfunctionPharmacoEconomics & outcomes news, 2021, Vol.882 (1), p.33-33Cham: Springer International PublishingTexto completo disponível |
|
5 |
Material Type: Artigo
|
NICE recommends pembrolizumab for advanced melanomaPharmacoEconomics & outcomes news, 2015-10, Vol.739 (1), p.35-35Cham: Springer International PublishingTexto completo disponível |
|
6 |
Material Type: Artigo
|
Alvimopan reduces costs in radical cystectomy for bladder cancerPharmacoEconomics & outcomes news, 2020, Vol.851 (1), p.3-3Cham: Springer International PublishingTexto completo disponível |
|
7 |
Material Type: Artigo
|
Influenza vaccination for age 50−64 cost beneficial in AustraliaPharmacoEconomics & outcomes news, 2019, Vol.836 (1), p.15-15Cham: Springer International PublishingTexto completo disponível |
|
8 |
Material Type: Artigo
|
STrAtegies for RelaTives doesn't increase costs of dementiaPharmacoEconomics & outcomes news, 2019, Vol.833 (1), p.31-31Cham: Springer International PublishingTexto completo disponível |
|
9 |
Material Type: Artigo
|
Intrapleural alteplase and domase alfa cost effectivePharmacoEconomics & outcomes news, 2019, Vol.829 (1), p.16-16Cham: Springer International PublishingTexto completo disponível |
|
10 |
Material Type: Artigo
|
Bevacizumab less costly, just as safe as ranibizumab in AMDPharmacoEconomics & outcomes news, 2014, Vol.712 (1), p.9-9Cham: Springer International PublishingTexto completo disponível |